Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Target Price
The average target price of SERA is 5.0 and suggests 67% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell